“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial looking at bortezomib with chemotherapy for amyloidosis (REVEAL)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at bortezomib with chemotherapy for people with newly diagnosed amyloidosis. It was supported by Cancer Research UK.
More about this trial
Amyloidosis is a rare condition that affects the bone marrow, the spongy substance in the centre of bones where blood cells are made. In people with amyloidosis, the bone marrow makes abnormal
These abnormal plasma cells make an abnormal protein (amyloid) that can build up in body tissues and affect the way some organs work. It can affect organs such as the kidneys, liver or heart.
We already knew from research that bortezomib and chemotherapy can be useful for people whose amyloidosis has come back after treatment. The research team hoped it would also be useful for people with newly diagnosed amyloidosis.
The aim of this trial was to compare different combinations of bortezomib and chemotherapy to find out which is best to treat people with amyloidosis. And to find out what the side effects of each combination are.
Summary of results
- 3 had bortezomib, dexamethasone and doxorubicin
- 3 had bortezomib, dexamethasone and cyclophosphamide
- 1 had bortezomib and dexamethasone
How to join a clinical trial
Dr Ashutosh Wechalekar
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUK/09/027.